盐诱导激酶1与肿瘤

doi:10.3760/cma.j.issn.1673-422X.2017.11.008

国际肿瘤学杂志 ›› 2017, Vol. 44 ›› Issue (11): 838-841.doi: 10.3760/cma.j.issn.1673-422X.2017.11.008

盐诱导激酶1与肿瘤

刘大威，贺德

524023 湛江，广东医科大学研究生院（刘大威）；南方医科大学附属深圳宝安医院普通外科（刘大威、贺德）

收稿日期:2017-04-10 出版日期:2017-11-08 发布日期:2017-11-24
通讯作者: 贺德 E-mail:hede1965@126.com
基金资助:
深圳市科技计划（JCYJ20160427192617570）

Salt-induced kinase 1 and tumors

Liu Dawei, He De

Department of General Surgery, Affiliated Bao′an Hospital of Southern Medical University, Shenzhen 518101, China

Received:2017-04-10 Online:2017-11-08 Published:2017-11-24
Contact: 贺德 E-mail:hede1965@126.com
Supported by:
Science and Technology Project of Shenzhen of China (JCYJ20160427192617570)

摘要/Abstract

摘要： 盐诱导激酶1（SIK1）与肿瘤的发生密切相关。研究表明SIK1在肝癌、胰腺癌、胃癌、肺癌、卵巢癌等肿瘤中的表达具有特异性，其异常表达能够抑制或促进肿瘤的发生、发展和转移。异常表达的SIK1有望为肿瘤的诊断和治疗提供新的方法，并对临床预后提供指导。

关键词: 肿瘤, 盐诱导激酶1

Abstract: Salt-inducible kinase 1 (SIK1) is closely related to tumorigenesis. The expressions of SIK1 in hepatocellular carcinoma, pancreatic cancer, gastric cancer, lung cancer, ovarian cancer and other tumors are specific, and their abnormal expressions can inhibit or promote the occurrence, development and metastasis of tumor. Abnormal expressions of SIK1 are expected to provide a new method for the diagnosis and treatment of tumors, and provide guidance for clinical prognosis.

Key words: Neoplasms, Saltinducible kinase 1

刘大威，贺德. 盐诱导激酶1与肿瘤[J]. 国际肿瘤学杂志, 2017, 44(11): 838-841.

刘大威，贺德. Salt-induced kinase 1 and tumors[J]. Journal of International Oncology, 2017, 44(11): 838-841.

参考文献

［1］ Du WQ, Zheng JN, Pei DS. The diverse oncogenic and tumor suppressor roles of saltinducible kinase (SIK) in cancer［J］. Expert Opin Ther Targets, 2016, 20(4): 477-485. DOI: 10.1517/14728222.2016.1101452. ［2］ Finsterwald C, Carrard A, Martin JL. Role of saltinducible kinase 1 in the activation of MEF2dependent transcription by BDNF［J］. PLoS One, 2013, 8(1): e54545. DOI: 10.1371/journal.pone.0054545. ［3］ Nixon M, StewartFitzgibbon R, Fu J, et al. Skeletal muscle salt inducible kinase 1 promotes insulin resistance in obesity［J］. Mol Metab, 2016, 5(1): 34-46. DOI: 10.1016/j.molmet.2015.10.004. ［4］ Kim MJ, Park SK, Lee JH, et al. Saltinducible kinase 1 terminates cAMP signaling by an evolutionarily conserved negativefeedback loop in βcells［J］. Diabetes, 2015, 64(9): 31893202. DOI: 10.2337/db141240. ［5］ Bertorello AM, Pires N, Igreja B, et al. Increased arterial blood pressure and vascular remodeling in mice lacking salt inducible kinase 1 (SIK1)［J］. Circ Res, 2015, 116(4): 642652. DOI: 10.1161/CIRCRESAHA.116.304529. ［6］ Eneling K, Chen J, Welch LC, et al. Saltinducible kinase 1 is present in lung alveolar epithelial cells and regulates active sodium transport［J］. Biochem Biophys Res Commun, 2011, 409(1): 28-33. DOI: 10.1016/j.bbrc.2011.04.100. ［7］ Qu C, He D, Lu X, et al. Saltinducible kinase (SIK1) regulates HCC progression and WNT/βcatenin activation［J］. J Hepatol, 2016, 64(5): 1076-1089. DOI: 10.1016/j.jhep.2016.01.005. ［8］ Qu C, Qu Y. Downregulation of saltinducible kinase 1 (SIK1) is mediated by RNF2 in hepatocarcinogenesis［J］. Oncotarget, 2017, 8(2): 31443155. DOI: 10.18632/oncotarget.13673. ［9］ Zou YF, Xie CW, Yang SX, et al. AMPK activators suppress breast cancer cell growth by inhibiting DVL3facilitated Wnt/βcatenin signaling pathway activity［J］. Mol Med Rep, 2017, 15(2): 899-907. DOI: 10.3892/mmr.2016.6094. ［10］ Chen Y, Huang Q, Zhou H, et al. Inhibition of canonical WNT/β-catenin signaling is involved in leflunomide (LEF)mediated cytotoxic effects on renal carcinoma cells［J］. Oncotarget, 2016, 7(31): 50401-50416. DOI: 10.18632/oncotarget.10409. ［11］ Fan D, Ren B, Yang X, et al. Upregulation of miR5015p activates the wnt/betacatenin signaling pathway and enhances stem celllike phenotype in gastric cancer［J］. J Exp Clin Cancer Res, 2016, 35(1): 177. DOI: 10.1186/s13046-016-0432-x. ［12］ Klose J, Eissele J, Volz C, et al. Salinomycin inhibits metastatic colorectal cancer growth and interferes with Wnt/betacatenin signaling in CD133+ human colorectal cancer cells［J］. BMC Cancer, 2016, 16(1): 896. DOI: 10.1186/s12885-016-2879-8. ［13］ Liu Y, Gao S, Chen X, et al. Overexpression of miR203 sensitizes paclitaxel (Taxol)resistant colorectal cancer cells through targeting the saltinducible kinase 2 (SIK2)［J］. Tumour Biol, 2016, 37(9): 1223112239. DOI: 10.1007/s13277-016-5066-2. ［14］ Miranda F, Mannion D, Liu S, et al. Saltinducible kinase 2 couples ovarian cancer cell metabolism with survival at the adipocyterich metastatic niche［J］. Cancer Cell, 2016, 30(2): 273289. DOI: 10.1016/j.ccell.2016.06.020. ［15］ Simard EP, Ward EM, Siegel R, et al. Cancers with increasing incidence trends in the United States: 1999 through 2008［J］. CA Cancer J Clin, 2012, 62(2): 118-128. DOI: 10.1016/j.juro.2012.06.090. ［16］ Ren ZG, Dong SX, Han P, et al. miR203 promotes proliferation, migration and invasion by degrading SIK1 in pancreatic cancer［J］. Oncol Rep, 2016, 35(3): 1365-1374. DOI: 10.3892/or.2015.4534. ［17］魏永永，侯静，唐文如，等. p53与Ras协同及其在肿瘤发生中的作用［J］. 遗传, 2012, 34（12）: 15131521. DOI: 10.3724/SP.J.1005.2012.01513. ［18］ Witte D, Zeeh F, Gdeken T, et al. Proteinaseactivated receptor 2 is a novel regulator of TGFβ signaling in pancreatic cancer［J］. J Clin Med, 2016, 5(12): 111. DOI: 10.3390/jcm5120111. ［19］ Demagny H, De Robertis EM. Point mutations in the tumor suppressor Smad4/DPC4 enhance its phosphorylation by GSK3 and reversibly inactivate TGFbeta signaling［J］. Mol Cell Oncol, 2016, 3(1): e1025181. DOI: 10.1080/23723556.2015.1025181. ［20］ Steigedal TS, Prestvik WS, Selvik LK, et al. Gastrininduced proliferation involves MEK partner 1 (MP1)［J］. In Vitro Cell Dev Biol Anim, 2013, 49(3): 162-169. DOI: 10.1007/s1162601395882. ［21］ Selvik LK, Rao S, Steigedal TS, et al. Saltinducible kinase 1 (SIK1) is induced by gastrin and inhibits migration of gastric adenocarcinoma cells［J］. PLoS One, 2014, 9(11): e112485. DOI: 10.1371/journal.pone.0112485. ［22］ Chen JL, Chen F, Zhang TT, et al. Suppression of SIK1 by miR141 in human ovarian cancer cell lines and tissues［J］. Int J Mol Med, 2016, 37(6): 1601-1610. DOI: 10.3892/ijmm.2016.2553. ［23］ Xu J, Wu W, Wang J, et al. miR367 promotes the proliferation and invasion of nonsmall cell lung cancer via targeting FBXW7［J］. Oncol Rep, 2017, 37(2): 1052-1058. DOI: 10.3892/or.2016.5314. ［24］ Meng X, Lu P, Fan Q. miR367 promotes proliferation and invasion of hepatocellular carcinoma cells by negatively regulating PTEN［J］. Biochem Biophys Res Commun, 2016, 470(1): 187191. DOI: 10.1016/j.bbrc.2016.01.025. ［25］ Chen W, Zheng R, Zeng H, et al. The updated incidences and mortalities of major cancers in China, 2011［J］. Chin J Cancer, 2015, 34(11): 502-507. DOI: 10.1186/s40880-015-0042-6. ［26］ Yao YH, Cui Y, Qiu XN, et al. Attenuated LKB1SIK1 signaling promotes epithelialmesenchymal transition and radioresistance of nonsmall cell lung cancer cells［J］. Chin J Cancer, 2016, 35: 50. DOI: 10.1186/s4088001601133. ［27］ Shaw RJ. Tumor suppression by LKB1: SIKness prevents metastasis［J］. Sci Signal, 2009, 2(86): e55. DOI: 10.1126/scisignal.286pe55. ［28］ Bai L, Lin G, Sun L, et al. Upregulation of SIRT6 predicts poor prognosis and promotes metastasis of nonsmall cell lung cancer via the ERK1/2/MMP9 pathway［J］. Oncotarget, 2016, 7(26): 40377-40386. DOI: 10.18632/oncotarget.9750. ［29］ Yang N, Cui H, Han F, et al. Paeoniflorin inhibits human pancreatic cancer cell apoptosis via suppression of MMP9 and ERK signaling［J］. Oncol Lett, 2016, 12(2): 1471-1476. DOI: 10.3892/ol.2016.4761.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

盐诱导激酶1与肿瘤

Salt-induced kinase 1 and tumors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价